Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).

CED Clinical Relevance  #64Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic CbdPediatricNeurodevelopmentalTransdermalOpen-Label JournalJournal of neurodevelopmental disordersStudy TypeOpen-Label TrialPopulationHuman participants Why This Matters22q11.2 deletion syndrome affects 1 in...

Read More